Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for Oxaliplatin-induced Hypersensitivity
NCT02266355Phase 1Completed
- Sponsor
- Yale University
- Start
- Nov 2014
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of omalizumab in drug hypersensitivity, sponsored by Yale University. Primary endpoint: Incidence of Recurrent Oxaliplatin-induced Hypersensitivity Reaction at 12 months. Started Nov 2014; status: completed.
02
Drugs
omalizumab
03
Conditions
drug hypersensitivity
Beyond the preview
Go deeper on NCT02266355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266355.